Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Leanne G. Ahronian; Soumyadip Sahu; Minjie Zhang; Ayushi Patel; Ke Geng; Reshmee Bhattacharya; Gerald S. Falchook; Jonathan W. Goldman; Alexander I. Spira; Salman R. Punekar; David R. Spigel; Judy S. Wang; Ferdinandos Skoulidis; Janaye Stephens; Mary Meynardie; Jaylen M. Powell; Alfonso Lopez; Michela Ranieri; Magdalena Ploszaj; Yi Jer Tan; Yeuan Ting Lee; Yi Yu; Jiehui Deng; Ting Chen; Patrick McCarren; Alice Tsai; Suleman S. Hussain; Brian Doyon; Kenjie Amemiya; Jacques Ermolieff; Preksha Shahagadkar; Nikitha M. Das; Lauren R. Flynn; Julie A. Shields; Laney Danielczyk; Brian J. McMillan; Andre Mignault; Samuel R. Meier; Hsin‐Jung Wu; David J. Guerin; Douglas A. Whittington; Chengyin Min; Iga Sienczylo; John P. Maxwell; Heather DiBenedetto; Hideo Watanabe; Brian B. Haines; Alan Huang; Adam S. Crystal; Jannik N. Andersen; Xinyuan Wu; Kwok‐Kin Wong

doi:10.1158/0008-5472.30363271

October 15, 2025

Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

View at Publisher

Ask AI

Bookmark

Share

Key Points

The small-molecule CoREST inhibitor sensitizes STK11-mutant tumors to anti-PD-1 immunotherapy, enhancing treatment efficacy.
CRISPR score analysis revealed differences in response between MC38_sgSTK11 tumors in C57BL/6 mice and athymic nude mice.
Comparison of tumor responses indicates that the treatment could improve immunotherapy outcomes for STK11-mutant cancers.
The findings suggest potential for integrating CoREST inhibitors into existing immunotherapy frameworks for better results.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis shows small-molecule CoREST inhibitor increases response to anti-PD-1 immunotherapy in STK11-mutant tumors, indicating potential therapeutic synergy.

Abstract

CRISPR score results for the comparison of MC38_sgSTK11 tumors in C57BL/6 mice treated with anti-PD-1 compared to MC38_sgSTK11 tumors in athymic nude mice

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahronian et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcb34 https://doi.org/10.1158/0008-5472.30363271

View at Publisher

Ask AI

Bookmark

Share

Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading